AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026Net selling: insiders sold $7.1M and bought $0 on the open market in 90 days (SEC Form 4). Congress: both buying and selling, $3K to $45K in total in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$7.1M netNet selling
- CongressSTOCK Act, last 180 days
- $3K to $45K tradedMixed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 10 added, 4 cutMore adding
Key stats
Fundamentals Sep 30- Open
- $849.29
- 52-wk high
- $996.84
- High
- $866.44
- 52-wk low
- $722.11
- Low
- $847.29
- Prev close
- $856.29
- Mkt cap
- $100.83B
- P/E
- 23.2x
- Volume
- 476.7K
- Fwd P/E
- 19.7x
- Beta
- 0.31
- Div yield
- 0.38%
- P/S
- 0.2x
- P/B
- 5.0x
- Profit margin
- +1.1%
- Op margin
- +1.4%
- ROE
- +0.0%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about MCK filings
Are insiders buying or selling McKesson Corporation (MCK) stock?
Net selling: insiders sold $7.1M and bought $0 of MCK stock on the open market in the 90 days to Oct 1, 2026, according to SEC Form 4 filings. $6.8M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Tyler, Brian S. (Chief Executive Officer), who sold $6.7M. The latest filing was on Sep 10, 2026.
Which members of Congress have traded MCK recently?
Rep. Rick Larsen (D) bought $1K to $15K on Jul 8, 2026, disclosed 4 days later. Rep. Jonathan Jackson (D) sold $1K to $15K on Jun 15, 2026, disclosed 30 days later. Rep. Elizabeth Fletcher (D) sold $1K to $15K on Apr 8, 2026, disclosed 23 days later. In total, 3 members disclosed 3 MCK trades with trade dates in the last 180 days, filed a median 23 days after trading.
How current is this MCK smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (2)
- DS
D.E. Shaw
$319.4M
added
- CI
Citadel
$282.8M
added
Sells/Trims (1)
- LP
Lone Pine
$295.7M
trimmed
What insiders are doing
What Congress is doing
Sells (1)
How top traders are positioned
No tracked top-trader positions in MCK right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 5.2% above what analysts expected.
Earnings per share
$9.44 expected
Revenue
$103.74B expected
GAAP EPS was $5.15 and adjusted EPS was $9.93. The adjusted figure is comparable to consensus.
Reports Nov 4, 2026, in 34 days
Estimates as of Sep 30, 2026
EPS expected
$10.53 to $11.26
Revenue expected
13 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $103.15B | $106.16B | $96.30B | $105.38B |
| Cost of what it sold | $99.61B | $102.47B | $92.25B | $101.69B |
| Gross profit | $3.54B | $3.69B | $4.04B | $3.69B |
| What it spent | ||||
| Sales and admin | $2.07B | $2.03B | $1.80B | $2.26B |
| Other operating costs | — | $36.0M | — | $102.0M |
| Total operating expenses | $2.07B | $2.07B | $1.80B | $2.37B |
| What was left | ||||
| Operating profit | $1.47B | $1.62B | $2.25B | $1.32B |
| Interest on debt | $74.0M | $63.0M | $61.0M | $77.0M |
| Profit before tax | $1.40B | $1.63B | $2.13B | $1.31B |
| Tax | $232.0M | $380.0M | $270.0M | $276.0M |
| Net profit | $1.11B | $1.19B | $1.68B | $614.0M |
| EBITDA | $1.66B | $1.84B | $2.26B | $1.39B |
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
25 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?
NeutralSep 29Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
Leans bullishSep 29McKesson stock falls 1.19 percent as targets split
NeutralSep 29AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?
NeutralSep 25AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?
NeutralSep 25McKesson (MCK) Lifted Its Guidance, Is The Stock Still 11% Undervalued?
Leans bullishSep 25Is Henry Schein Stock Outperforming the Dow?
Leans bullishSep 25McKesson stock heads into the open after a 0.1 percent gain
Leans bullishSep 25
Macro
32 macro signals shaping MCK right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results